Video | TCTAP 2023

[Hot Topics] All About New Data of Antithrombotics

May 7, 2023, 2:40 PM ~ 4:10 PM | Valve & Endovascular Theater, Vista 1, B2

Moderator(s): Hyo-Soo Kim, Pieter Smits
Panelist(s): Junya Ako, Aloke V. Finn, Joo-Yong Hahn, Young-Hoon Jeong, Chan Joon Kim, Michael S. Lee, Mamas Mamas, Yongwhi Park

  • Modulation of DAPT Duration: Risk-benefit of 1-year DAPT
    Tullio Palmerini
  • Clopidogrel Monotherapy After Short-term DAPT in Patients who Underwent PCI using DES
    Takeshi Kimura
  • P2Y12 Inhibitor or Asprin for Long-term Antiplatelet Management
    Kyung Woo Park
  • Recommendation, Guided vs. Potent P2Y12 Inhibitor Therapy: Updated Evidence
    Pieter Smits
  • Panel Discussion I
  • Edoxaban vs. DAPT for Valve Thrombosis and Cerebral Thromboembolism After TAVR: Deep-Dive into ADAPT-TAVR Trial
    Duk-Woo Park
  • Updated Evidence and Recommendation of Antithrombotic Therapy after TAVR
    George D. Dangas
  • Next Novel Antithrombotic Drugs for ACS/PCI: Oral Factor XIa inhibitor or More
    Roxana Mehran
  • BRIGHT-4 Trial; Bivalirudin with a Post-PCI High-Dose Infusion vs. Heparin Monotherapy During Primary PCI in STEMI
    Gregg W. Stone
  • Panel Discussion II

Leave a comment

Sign in to leave a comment.